Skip to main content
Top
Published in: Intensive Care Medicine 12/2006

01-12-2006 | Brief Report

Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients

Authors: Jean-Marie Conil, Bernard Georges, Olivier Mimoz, Eric Dieye, Stéphanie Ruiz, Pierre Cougot, Kamran Samii, Georges Houin, Sylvie Saivin

Published in: Intensive Care Medicine | Issue 12/2006

Login to get access

Abstract

Objective

To explore the effects of renal function estimated by measured creatinine clearance (ClCR) on trough serum concentration (Cmin) of piperacillin given to critically ill patients.

Design

Prospective observational study.

Setting

An intensive care unit and research ward in a university hospital.

Patients

Seventy critically ill patients, including 22 with severe trauma.

Interventions

All subjects received an intravenous infusion of piperacillin 4 g three times (n = 61) or four times (n = 9) per day. Piperacillin Cmin values were determined 24 h after treatment started and compared to the French breakpoint defining antibiotic susceptibility against Enterobacteriaceae (8 mg/l) or Pseudomonas sp. (16 mg/l).

Results

Median (range) piperacillin Cmin was 11.9 (< 1–156.3) mg/l, with a great variability among patients. Although the median value was close to the breakpoints, sub-therapeutic plasma levels were frequently observed. Piperacillin Cmin was lower than the breakpoint for Enterobacteriaceae in 37% of patients, and lower than the breakpoint for P. aeruginosa in 67% of them. A strong relationship was observed between piperacillin Cmin and ClCR: the higher the ClCR, the lower the piperacillin Cmin in serum. For patients with a ClCR < 50 ml/min, enough piperacillin Cmin was achieved in most patients with 12 g piperacillin per day. For patients with higher ClCR values, a piperacillin daily dose of 16 g or more may be warranted.

Conclusions

In critically ill patients, therapeutic monitoring must be part of the routine, and knowledge of ClCR value may be useful for the choice of adequate initial piperacillin dosing.
Literature
1.
go back to reference Perry CM, Markham A (1999) Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs 57:805–843PubMedCrossRef Perry CM, Markham A (1999) Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs 57:805–843PubMedCrossRef
2.
go back to reference Vondracek TG (1995) Beta-lactam antibiotics: is continuous infusion the preferred method of administration? Ann Pharmacother 29:415–424PubMed Vondracek TG (1995) Beta-lactam antibiotics: is continuous infusion the preferred method of administration? Ann Pharmacother 29:415–424PubMed
3.
go back to reference Craig WA, Ebert SC (1992) Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 36:2577–2583PubMed Craig WA, Ebert SC (1992) Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 36:2577–2583PubMed
4.
go back to reference Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP (2002) Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H. Chemotherapy 48:59–63PubMedCrossRef Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP (2002) Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H. Chemotherapy 48:59–63PubMedCrossRef
5.
go back to reference Lipman J, Wallis SC, Rickard C (1999) Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 43:2559–2561PubMed Lipman J, Wallis SC, Rickard C (1999) Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 43:2559–2561PubMed
6.
go back to reference Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, Boucher BA (2000) Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 179:436–440PubMedCrossRef Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, Boucher BA (2000) Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 179:436–440PubMedCrossRef
7.
go back to reference Mehrotra R, De Gaudio R, Palazzo M (2004) Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 30:2145–2156PubMedCrossRef Mehrotra R, De Gaudio R, Palazzo M (2004) Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 30:2145–2156PubMedCrossRef
8.
go back to reference Brown R, Babcock R, Talbert J, Gruenberg J, Czurak C, Campbell M (1980) Renal function in critically ill postoperative patients: sequential assessment of creatinine osmolar and free water clearance. Crit Care Med 8:68–72PubMedCrossRef Brown R, Babcock R, Talbert J, Gruenberg J, Czurak C, Campbell M (1980) Renal function in critically ill postoperative patients: sequential assessment of creatinine osmolar and free water clearance. Crit Care Med 8:68–72PubMedCrossRef
9.
go back to reference Lipman J, Wallis SC, Boots RJ (2003) Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 97:1149–1154PubMedCrossRef Lipman J, Wallis SC, Boots RJ (2003) Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 97:1149–1154PubMedCrossRef
10.
go back to reference Ocampo AP, Hoyt KD, Wadgaonkar N, Carver AH, Puglisi CV (1989) Determination of tazobactam and piperacillin in human plasma, serum, bile and urine by gradient elution reversed-phase high-performance liquid chromatography. J Chromatogr 496:167–179PubMed Ocampo AP, Hoyt KD, Wadgaonkar N, Carver AH, Puglisi CV (1989) Determination of tazobactam and piperacillin in human plasma, serum, bile and urine by gradient elution reversed-phase high-performance liquid chromatography. J Chromatogr 496:167–179PubMed
11.
go back to reference Shikuma LR, Ackerman BH, Weaver RH, Solem LD, Strate RG, Cerra FB, Zaske DE (1990) Effects of treatment and the metabolic response to injury on drug clearance: a prospective study with piperacillin. Crit Care Med 18:37–41PubMedCrossRef Shikuma LR, Ackerman BH, Weaver RH, Solem LD, Strate RG, Cerra FB, Zaske DE (1990) Effects of treatment and the metabolic response to injury on drug clearance: a prospective study with piperacillin. Crit Care Med 18:37–41PubMedCrossRef
12.
go back to reference Jehl F, Muller-Serieys C, de Larminat V, Monteil H, Bergogne-Berezin E (1994) Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients. Antimicrob Agents Chemother 38:2780–2784PubMed Jehl F, Muller-Serieys C, de Larminat V, Monteil H, Bergogne-Berezin E (1994) Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients. Antimicrob Agents Chemother 38:2780–2784PubMed
13.
go back to reference Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmele T, Chassard D, Saux MC, Allaouchiche B (2004) Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 30:976–979PubMedCrossRef Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmele T, Chassard D, Saux MC, Allaouchiche B (2004) Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 30:976–979PubMedCrossRef
14.
go back to reference Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ (1995) The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 28:143–160PubMedCrossRef Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ (1995) The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 28:143–160PubMedCrossRef
15.
go back to reference Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD (2005) Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 25:62–67PubMedCrossRef Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD (2005) Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 25:62–67PubMedCrossRef
16.
go back to reference Johnson CA, Halstenson CE, Kelloway JS, Shapiro BE, Zimmerman SW, Tonelli A, Faulkner R, Dutta A, Haynes J, Greene DS, et al. (1992) Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther 51:32–41PubMedCrossRef Johnson CA, Halstenson CE, Kelloway JS, Shapiro BE, Zimmerman SW, Tonelli A, Faulkner R, Dutta A, Haynes J, Greene DS, et al. (1992) Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther 51:32–41PubMedCrossRef
17.
go back to reference Westphal JF, Brogard JM, Caro-Sampara F, Adloff M, Blickle JF, Monteil H, Jehl F (1997) Assessment of biliary excretion of piperacillin-tazobactam in humans. Antimicrob Agents Chemother 41:1636–1640PubMed Westphal JF, Brogard JM, Caro-Sampara F, Adloff M, Blickle JF, Monteil H, Jehl F (1997) Assessment of biliary excretion of piperacillin-tazobactam in humans. Antimicrob Agents Chemother 41:1636–1640PubMed
18.
go back to reference Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP (2005) Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 56:388–395PubMedCrossRef Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP (2005) Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 56:388–395PubMedCrossRef
19.
go back to reference Brunner M, Pernerstorfer T, Mayer BX, Eichler HG, Muller M (2000) Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med 28:1754–1759PubMedCrossRef Brunner M, Pernerstorfer T, Mayer BX, Eichler HG, Muller M (2000) Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med 28:1754–1759PubMedCrossRef
Metadata
Title
Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients
Authors
Jean-Marie Conil
Bernard Georges
Olivier Mimoz
Eric Dieye
Stéphanie Ruiz
Pierre Cougot
Kamran Samii
Georges Houin
Sylvie Saivin
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
Intensive Care Medicine / Issue 12/2006
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-006-0421-1

Other articles of this Issue 12/2006

Intensive Care Medicine 12/2006 Go to the issue

Legal and Ethical Issues in Clinical Research

The Nuremberg doctors' trial: the 60th anniversary